August 27, 2014

The International Society for Pharmaceutical Engineering on Wednesday announced that it has released a preview of its Drug Shortages Prevention Plan aimed at helping the pharmaceutical industry avoid drug shortages and maintain a reliable supply of medications. 

June 23, 2014

America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report released by the Pharmaceutical Research and Manufacturers of America last week.

June 19, 2014

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

June 18, 2014

Canada’s Federal Court ruled recently that the country’s Patented Medicine Prices Review Board — a federal tribunal that regulates pricing on branded medicines — could not extend price-control measures to cover generic drug companies, according to published reports.

June 10, 2014

Canada’s Federal court ruled recently that the country’s Patented Medicine Prices Review Board – a federal tribunal that regulates pricing on branded medicines – could not extend price control measures to cover generic drug companies.

April 22, 2014

Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports.

March 6, 2014

McKesson on Wednesday announced that its board of directors has elected Anthony Coles as a new independent director, effective April 29, 2014.

February 7, 2014

Novartis Consumer Health on Thursday announced that Todd Hutsko has been appointed head of sales U.S., effective March 1.

November 11, 2013

Swiss drug maker Novartis is selling its blood transfusion diagnostics business to a Spanish manufacturer for $1.7 billion, Novartis said Monday.

October 15, 2013

AstraZeneca has acquired a British developer of biotech drugs for treating cancer, AstraZeneca said Tuesday.

October 8, 2013

Consumers in the United States are more likely than those in three other countries to say they prefer to receive generic drugs over branded drugs, according to a new study.

September 23, 2013

Sandoz has launched an authorized generic drug for treating a disease commonly known as pre-leukemia, the company said on Monday.

August 13, 2013

The U.S. Food and Drug Administration this past weekend announced new fee rates for fiscal year 2014, including the abbreviated new drug application fee.

July 26, 2013

A federal court has ruled in favor of generic drug maker Sandoz in a case involving a drug for multiple sclerosis, Sandoz said.

May 21, 2013

Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

May 10, 2013

Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said.

April 17, 2013

Generic drug maker Sandoz has launched a generic version of a drug used to treat high blood pressure and angina.

March 12, 2013

Actavis is challenging Novartis' patent on a patch used to treat Alzheimer's disease, Actavis said.

October 16, 2012

The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

October 16, 2012

Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

September 4, 2012

Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.

August 17, 2012

The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries.

August 17, 2012

Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

August 17, 2012

Teva Pharmaceutical Industries announced the launch of an authorized generic of a Type 2 diabetes drug.